Autocrine Regulation of Keratinocytes: The Emerging Role of Heparin-Binding, Epidermal Growth Factor-Related Growth Factors  by Piepkorn, Michael et al.
REVIEW ARTICLE
Autocrine Regulation of Keratinocytes: The Emerging Role of
Heparin-Binding, Epidermal Growth Factor-Related Growth
Factors
Michael Piepkorn, Mark R. Pittelkow,* and Paul W. Cook†
Departments of Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, U.S.A.; *Departments of Dermatology and
Biochemistry and Molecular Biology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, U.S.A.; †Departments of Dermatology and Cell and
Developmental Biology, Oregon Health Sciences University, Portland, Oregon, U.S.A.
Although originally conceived as a basis for malignant
cell growth, autocrine signaling networks are currently
known to be activated during tissue repair and with
in vitro cultivation. In human epidermal keratinocytes,
activation of the epidermal growth factor receptor by
cognate ligands mediates the majority of the autonomous
replicative capacity of these cells and is necessary to
inhibit differentiation and apoptosis. The importance
of heparin-binding growth factors in activation of this
receptor was first suggested by the strong anti-proliferat-
ive effects of soluble heparin-like molecules on ker-
atinocyte growth. This and related evidence led to the
identification of amphiregulin as a major autocrine factor
for keratinocytes. The binding of amphiregulin and its
homolog, heparin-binding epidermal growth factor-like
growth factor, to the receptor is potentially amplified
by autoinduction and cross-signaling through epidermal
growth factor-related polypeptides and by transmodula-
tion of other ErbB-family receptors (HER-2, -3, -4) in
cells expressing these receptors. Heparan sulfate proteo-
The concept of autocrine cellular signaling was originallyinvoked to explain the unregulated, autonomousproliferation of malignant cells (Sporn and Todaro,1980). It was postulated that dysregulated cellularproliferation results from endogenous production of
growth-promoting polypeptides (transforming growth factors) and
constitutive activation of cognate receptors, thereby supplanting the
dependency on exogenous growth factors. The model further
postulated that these mechanisms do not normally function in
nontransformed cells except during embryogenesis, but that inappro-
priate and coordinate expression of these factors is activated with
malignant transformation (Sporn and Todaro, 1980; Alexander and
Currie, 1984). Notably, much of the investigations supporting these
original tenets derived from in vitro studies on rodent fibroblasts.
Revisions of the concept followed the discovery that autocrine
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glycans and the tetraspanin family of membrane-associ-
ated proteins appear to act as cofactors in amphiregulin-
driven mitogenesis mediated by the epidermal growth
factor receptor, but amphiregulin’s immunolocalization
to keratinocyte nuclei and to filopodia may indicate other
potentially novel effects. Following from the observation
that amphiregulin is overexpressed in lesional psoriatic
epidermis, the importance of amphiregulin in hyperprol-
iferative skin diseases has been further supported by
recent studies of the targeted expression of a transgene
encoding keratin 14 promoter-driven human amphiregu-
lin to the basal epidermis of mice. Founder transgenic
mice displayed a morphologic and microscopic cutaneous
phenotype that shares characteristics with psoriasis. Phar-
macologic regulation of amphiregulin’s expression and
receptor signaling may eventually prove to be an effective
strategy in the treatment of hyperproliferative skin dis-
eases. Key words: amphiregulin/autocrine growth/epidermal
growth factor receptor/heparin-binding epidermal growth factor-
like growth factor. J Invest Dermatol 111:715–721, 1998
pathways are expressed in normal cells and are inducible under
various situations, such as during tissue repair (Stiles, 1984;
Marikovsky et al, 1993; Liou et al, 1997) or when normal epithelial
cells such as epidermal keratinocytes and mammary epithelial cells
are cultured in vitro (Coffey et al, 1987a, b; Shipley et al, 1989;
Cook et al, 1991a; Li and Shipley, 1991; Li et al, 1992; Piepkorn
et al, 1994; Stoll et al, 1997). Following from our current
understanding of autocrine regulation of various epithelial tissues
and organs, autocrine dysregulation emerges as a potential mechanism
contributing to the pathophysiology of those disease states that
manifest aberrant hyperproliferation. Thus, the growth factors of
autocrine regulatory networks hold promise as targets for therapeutic
intervention through pharmacologic control of their expression,
interaction with cognate cell surface receptors, or their coupled
downstream signal transduction pathways.
THE EPIDERMAL GROWTH FACTOR RECEPTOR
SIGNALING AXIS
Contrary to early claims that only malignantly transformed cells display
autocrine-driven proliferation in culture (Sporn and Todaro, 1980;
Alexander and Currie, 1984), we and others have shown that normal
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human keratinocytes exhibit autonomous (autocrine growth factor
driven) proliferation when cultured at cell densities above 1 3 103
cells per cm2 (Shipley et al, 1989; Cook et al, 1991a; Pittelkow et al,
1993; Piepkorn et al, 1994). With the exception of acidic fibroblast
growth factor and keratinocyte growth factor, human keratinocytes
appear to require binding of epidermal growth factor (EGF) or other
family member ligands to the EGF receptor (EGFR, human EGFR-1,
or HER-1) to sustain proliferation in culture (Rheinwald and Green,
1977; Finch et al, 1989; Shipley et al, 1989; Pittelkow et al, 1993).
Current understanding of autocrine signaling in epidermal keratinocytes
thus assigns a principal function to the EGFR/HER-1 and its specific
ligands. The primary role of the EGF receptor-ligand system as an
endogenous signaling axis in keratinocytes is reflected by the observation
that blocking antibody against the EGFR inhibits greater than –90%
of autocrine growth of these cells in vitro (Cook et al 1991b; Pittelkow
et al, 1993; Piepkorn et al, 1994; Ristow, 1996; Peus et al, 1997). More
recent investigation has also demonstrated that interruption of the
activity of EGF-related autocrine growth factors in human keratinocytes
by neutralizing antibody to the EGFR, or a specific inhibitor of the
EGFR tyrosine kinase (PD 153035), not only causes cessation of
keratinocyte proliferation, but also induces irreversible growth arrest
and terminal differentiation (Peus et al, 1997). The correlation between
keratinocyte proliferation and expression of the EGFR is further
illustrated by immunolabeling, which localizes the receptor to the
proliferative basal compartment in adult epidermis, as well as to all
epidermal layers and appendages of fetal skin (Nanney et al, 1990;
Sakai et al, 1994). EGFR null mice, moreover, exhibit severe epidermal
atrophy, markedly diminished basal rates of epidermal keratinocyte
replication, and premature differentiation (Miettinen et al, 1995; Sibilia
and Wagner, 1995; Threadgill et al, 1995).
EGF and its homolog, transforming growth factor-α (TGF-α), were
originally considered the principal ligands for the EGFR in keratinocytes
(Rheinwald and Green, 1977; Wille et al, 1984; Coffey et al, 1987a, b;
Pittelkow et al, 1988, 1989). The importance of heparin-binding
autocrine factors in keratinocytes, however, first emerged from the
observation that exogenous heparin-like glycosaminoglycans strongly
inhibit the autonomous growth of these cells (Shipley et al, 1989;
Cook et al, 1991a, 1992b; Piepkorn et al, 1994), whereas both EGF
and TGF-α were shown to lack heparin-binding and heparin-mediated
regulation in human keratinocytes (Cook et al, 1991b). Juxtacrine-
mediated autonomous growth has also been implicated in normal
keratinocytes as we have shown that colonies of at least 4–10 cells are
required for the heparin-inhibitable, EGF-receptor-dependent clonal
expansion of these cells in the absence of exogenous growth factors
(Pittelkow et al, 1993). Subsequently, as the list of EGF homologs has
expanded, several ligands have been identified with binding affinity
for heparinoids. Specifically, an EGF-related ligand named amphiregulin
(AR) has been implicated in mediating the autocrine growth and
heparin-dependent growth inhibition of normal epithelial (e.g., epi-
dermal or mammary) cells derived from ectoderm (Cook et al, 1991a;
Li and Shipley, 1991, 1992b; Li et al, 1992; Piepkorn et al, 1994).
AR is a member of the EGF family with sequence homology within
its carboxy-terminal domain to EGF and TGF-α (Shoyab et al, 1988,
1989; Plowman et al, 1990; Cook et al, 1991b) and is presently
identified as a major autocrine factor responsible for the autonomous
proliferation of human keratinocytes when cultured under serum free
conditions in the absence of exogenous EGF or bovine pituitary extract
(Cook et al, 1991b; Piepkorn et al, 1994). The homolog, heparin-
binding EGF-like growth factor (HB-EGF) (Higashiyama et al, 1992),
may also exert some autocrine effects in these cells (Hashimoto et al,
1994). By blocking antibody studies, AR and HB-EGF account for
–70% (Piepkorn et al, 1994) and less than 30% (Hashimoto et al, 1994),
respectively, of autocrine-dependent proliferation. The molar mitogenic
potency of human recombinant AR with murine and human keratino-
cytes is also comparable with that of EGF (Shoyab et al, 1989; Cook
et al, 1991b; Piepkorn et al, 1994).
Because HB-EGF shares with AR a strong sequence homology
(Higashiyama et al, 1992), a common pathway of signal transduction
through the EGFR (Higashiyama et al, 1992), and an apparent
requirement for cell surface heparin-like glycosaminoglycans as cofactors
in at least some cell lineages (Higashiyama et al, 1993; Aviezer and Yayon,
1994; Johnson and Wong, 1994; Piepkorn et al, 1994; Thompson et al,
1994; Cook et al, 1995b), it is presumed for the purposes of this
overview that the functional activities of the two factors are similar
and, perhaps, partly redundant. One curious difference, however, is
that the mitogenic activity of HB-EGF in various cells including
keratinocytes is variably potentiated by soluble heparinoids (Marikovsky
et al, 1993; Cook et al, 1995a), in stark contrast to their attenuative
effects on AR signaling (Cook et al, 1991b, 1992b, 1995a; Piepkorn
et al, 1994); the enhancing effect of the HB-EGF depends on a
conserved leucine residue (leu76) near the carboxyl terminus, which is
absent in the AR coding sequence (Cook et al, 1995a).
MOLECULAR BIOLOGY OF AMPHIREGULIN
At the genomic level, the single copy gene for AR maps to chromosome
4q13–21 and is partitioned into six exons covering 10.2 kb of genomic
DNA (Plowman et al, 1990). As deduced from the cDNA clone, the
translation product is a prepropeptide of 252 amino acids, predicting
a mass without glycosylation of 25.9 kDa. The domain structure of
the deduced precursor conforms to a type I transmembrane protein,
with extracellular, membrane spanning, and cytoplasmic tail domains.
The mature, secreted growth factor, originally considered to be either
78 or 84 residues in length, is embedded within the precursor and is
processed from the ectodomain after membrane insertion (Plowman
et al, 1990); however, recombinant AR isoforms with carboxy-terminal
extensions have substantially higher mitogenic activities than the
recombinant 84 residue molecule, suggesting that the actual terminus
of native AR may be more distal than originally thought (Adam
et al, 1995; Thompson et al, 1996). The soluble species contains an
N-terminal, hydrophilic segment with two putative binding sites for
heparin-like glycosaminoglycans, at positions 125–129 (KRKKK) and
140–143 (RKKK), and a 41-residue carboxy terminus with the EGF-
like motif of six conserved cysteinyl residues that are presumed to form
three disulfide loops (Plowman et al, 1990). Cellular processing
and secretion of AR are modulated via extensive post-translational
modification by N-linked glycosylation, creating isoforms with varying
biologic properties (Johnson et al, 1993b; Thome and Plowman, 1994;
Martinez-Lacaci et al, 1996). The release of multiple soluble AR
isoforms of varying molecular mass has been shown to occur from a
common, membrane-anchored precursor at the plasma membrane by
a phorbol ester-regulated process that is sensitive to a metalloprotease
inhibitor (Brown et al, 1998) (Fig 1).
Soluble, secreted AR apparently exerts its tyrosine phosphorylation
and mitogenic effects largely, if not exclusively, through binding and
activation of the 170 kDa EGFR (Johnson et al, 1993a; Piepkorn et al,
1994; Peus et al, 1997; Pittelkow et al, unpublished observations)
(Fig 1). In support of this mechanism of action, AR and the EGFR
partially colocalize by dual immunolabeling in cultured keratinocytes
to sites of intercellular contacts (Nylander et al, 1998). Other effects
of AR, however, may be mediated by separate pathways because the
factor segregates under some growth conditions to the nucleus by
scanning laser confocal microscopy of the immunolabeled cells, without
evidence for coordinate intranuclear targeting of the EGFR (Nylander
et al, 1998). Moreover, immunolabeled AR decorates filopodia at
the outer leading edges of keratinocyte colonies, suggesting matrix
interactions (Nylander et al, 1998).
Signal transduction following ligand activation of the EGFR tyrosine
kinase involves broadly conserved downstream effectors (van der Geer
et al, 1994). Ligand engagement induces receptor dimerization, activates
intrinsic tyrosine kinase, and stimulates trans- and autophosphorylation
at specific tyrosyl residues of the receptor. Phosphotyrosines are bound
by the adapter molecule GRB2 via its src homology 2 (SH2) domain;
coupling of the signal through phosphorylation of a factor, SOS,
stimulates guanine nucleotide exchange activity, activating the ras
proto-oncogene product. Downstream effects on transcriptional factors
that regulate gene expression are controlled, in part, by the mitogen-
activated protein or extracellular regulated kinase cascade that is linked
to ras activation. There is complex redundancy and cross-regulation
between the factors that act through the EGFR (Barnard et al, 1994;
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Ebert et al, 1994; Hashimoto et al, 1994; Sehgal et al, 1994). Signal
amplification is achieved by autoinduction of AR mRNA and protein,
as well as by cross-signaling from EGF, TGF-α, or HB-EGF and
potentially by transmodulation from the ErbB-(HER)-2, -3, and -4
receptors, which are homologs of the EGFR (Barnard et al, 1994; Beerli
and Hynes, 1996) (Fig 2). Whether downstream signal transduction
pathways via EGFR activation are qualitatively different in relation to
which EGF-related ligands engage the receptor is not clearly defined
at present.
Figure 1. Membrane-anchored pro-AR is proteolytically processed at
the plasma membrane into multiple soluble isoforms. The transmembrane
precursor is partitioned into five structural domains. The common processing
site within the carboxyl-terminus of the EGF-like domain is indicated by the
dashed arrows at the plasma membrane. Cleavage of the pro-domain and at
additional candidate sites (arrows) within the hydrophilic domain creates secretory
isoforms that vary in relative mass from 9 to 43 kDa.
Figure 2. The signaling of heparin-binding,
EGF-like ligands through the HER-family
of receptors is regulated by heparinoids.
Activation of the intrinsic tyrosine kinase
domains of EGFR (HER-1), HER-4, and
perhaps other homologs initiates signal trans-
duction following ligation of EGF, TGF-α,
AR, or HB-EGF. In contrast to the signaling
of EGF and TGF-α (far right), the interaction
of AR and HB-EGF with cognate receptors
requires a membrane heparan sulfate proteo-
glycan as an obligate cofactor, depicted as a
hypothetical ternary signaling complex. Soluble
heparin-like molecules act as competitive
inhibitors of the proteoglycan for binding of
growth factor, thereby abrogating signaling
through HER-1 and, in the case of HB-EGF,
HER-4. There is, however, evidence that HB-
EGF may also ligate an uncharacterized receptor
and signal without an obligate proteoglycan
cofactor.
AMPHIREGULIN SIGNALING COMPLEX
Activation of the EGFR by TGF-α and EGF is independent of any
requirement for cellular proteoglycans as obligate cofactors; in contrast,
experimental observations indicate that receptor activation by AR
(Johnson and Wong, 1994; Piepkorn et al, 1994; Cook et al, 1995b)
and, at least in some cell types, HB-EGF (Higashiyama et al, 1993),
requires endogenous membrane heparan sulfate proteoglycans as
obligate cofactors. In other cell types such as mouse fibroblasts and
keratinocytes, however, the signaling of HB-EGF might occur through
alternative proteoglycan independent pathways utilizing receptors other
than those that interact with either EGF or TGF-α (Cook et al, 1995b)
(Fig 2). In the case of AR effects on cultured human keratinocytes, a
trimolecular signaling complex of ligand, proteoglycan, and the EGFR
has been hypothesized (Johnson and Wong, 1994; Piepkorn et al, 1994;
Cook et al, 1995b) (Fig 2). As such, the molecular interactions may
be analogous to fibroblast growth factors (FGF) signaling through their
specific tyrosine kinase receptors. Extrapolating from the model of
FGF signal transduction, the binding of AR to the heparan sulfate
chains of a membrane proteoglycan could be mediated by the two
strongly basic loci within the amino terminus of the mature factor
(Plowman et al, 1990), which would serve to present the ligand to the
EGFR. The basic residues, however, may also function as recognition
sequences for nuclear targeting (Plowman et al, 1990), as reflected in
reports of the nuclear localization of AR in several cell types, including
human keratinocytes (Johnson et al, 1991, 1992; Modrell et al, 1992;
Normanno et al, 1993; Piepkorn et al, 1995). The evidence at present
is consistent with at least two alternative models for AR and/or HB-
EGF signaling at the cell surface. As with FGF signaling (Olwin
and Rapraeger, 1992; Kan et al, 1993), membrane heparan sulfate
proteoglycans could bind growth factor and present it to the receptor
in an optimal conformation for activating the receptor. Alternatively,
heparan sulfate proteoglycan with its multivalent glycosaminoglycan
chains may bridge contiguous receptors directly or via the growth
factor as linker molecule, promoting receptor oligomerization. Potential
regulatory targets under these alternate models include variations in
affinity between the glycosaminoglycan and growth factor, due in part
to changes in heparan sulfate structure related to the growth status of
the cells, or enzymatic deglycosylation of heparan sulfate proteoglycans
occurring on the cell surface, which could strongly downregulate signal
transduction (Piepkorn et al, 1987, 1988, 1990, 1994).
It is not clear which specific proteoglycans regulate signaling of AR
and other heparin-binding growth factors. Syndecans, a class of hybrid
membrane proteoglycans, can bind FGF in vitro (Chemousov and
Carey, 1993; Aviezer et al, 1994) and can support the signaling of
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Figure 3. Juxtracrine receptor activation
of keratinocytes is mediated via pro-AR or
pro-HB-EGF, in association with heparan
sulfate proteoglycans and/or CD9/Drap
27. Signaling between adjacent keratinocytes
involves the ligation of membrane-intercalated
growth factors, depicted as complexes with
either heparan sulfate proteoglycan (A), CD9/
Drap 27 (B), or both (C), to receptors on
adjacent keratinocytes.
FGF-2 through its cognate receptor (Steinfeld et al, 1996). Among the
various heparan sulfate proteoglycans synthesized by keratinocytes,
alternatively spliced CD44 isoforms are plausible candidates for obligate
cofactors in the membrane-based signaling of AR and other heparin-
binding growth factors. Keratinocytes synthesize high molecular weight
isoforms spliced with variant exon V3 (Kugelman et al, 1992), the
splicing of which in recombinant systems is associated with glycanation
by heparan sulfate chains and with the acquisition of affinity for
heparin-binding growth factors in ligand blot assays (Bennett et al,
1995). The candidate coreceptor role of CD44 isoforms in AR signaling
has been evaluated by correlating its topographical distribution with
those of AR and the EGFR. By dual immunostaining and imaging
with scanning laser confocal microscopy, CD44 and the EGFR
colocalize with AR to sites of intercellular contacts in the interior of
keratinocyte colonies (Nylander et al, 1998). This coordinate segregation
is consistent with a concerted function. At these sites, signaling of the
soluble growth factor or its membrane-anchored precursor is presum-
ably mediated via ligation of the EGFR, with the CD44 proteoglycan,
or another proteoglycan, serving as an obligate cofactor.
Another cell surface-associated family of proteins, transmembrane 4
(TM4) or tetraspanin super family that include CD9, has also been
shown to be involved in the upregulation of membrane-anchored HB-
EGF and AR (Inui et al, 1997; Maecker et al, 1997). Juxtacrine growth
activity is enhanced by coexpression of CD9 with pro-HB-EGF or
pro-AR in mouse L-cells, and anti-CD9 antibodies neutralize juxtacrine
activity of pro-HB-EGF (Fig 3). Approximately half the growth
activity of cultured keratinocytes is inhibited by anti-CD9 antibody, and
CD9 coprecipitates with pro-HB-EGF and pro-AR (Inui et al, 1997).
ALTERNATE SITES OF CELLULAR FUNCTION
It has been postulated that basic FGF and possibly other heparin-
binding growth factors, are ligated to their receptors on the cell surface
and routed by endocytosis to cytoplastmic and intranuclear sites as
molecular complexes with heparan sulfate glycosaminoglycans (Amalric
et al, 1994; Hawker and Granger, 1994). In studies evaluating the
possibility that AR is similarly routed, the nuclear localization of the
growth factor was observed to be accentuated in growth-arrested
keratinocytes (Nylander et al, 1998). This correlates with the prior
observation that it is predominantly restricted to the occasional nuclei
of spinous keratinocytes in normal adult human epidermis (Piepkorn
et al, 1995), but its expression is markedly upregulated in the cytoplasm
and cell membranes in hyperproliferative lesions (Piepkorn, 1996).
Nuclear transport of the growth factor may therefore serve as an
alternative signaling pathway exerting an attenuative effect on growth
in some cell types. In contrast, the ability of rat AR to mediate nuclear
targeting-dependent mtitogenic activity in the apparent absence of
EGF-receptor tyrosine kinase activity (Kimura, 1993) argues that
nuclear localization may be an important component of AR-dependent
mitogenic signaling in other cell types.
Autocrine signaling pathways may mediate, in part, the effects of
cell–matrix interactions on the cellular phenotype (Nakamura et al,
1995). The growth and motility of keratinocytes, as with other
nontransfiormed cells, are strongly controlled by intercellular and cell–
matrix contacts. Heparin-binding growth factors have recently been
linked to adhesive mechanisms (Nakamura et al, 1995). Integrins,
which are heterodimers of α and β subunits, mediate many processes
related to cell adhesion and motility, matrix and cytoskeletal re-
organization, and signal-transducing phosphorylation events through
tightly coordinated binding of their extracellular domains to insoluble
proteins of the extracellular matrix or to counter receptors on adjacent
cells (Schwartz et al, 1995). Additional effects are mediated via second
messengers (e.g., PKC, PTK, mitogen-activated protein kinases) that
activate early response genes. Of the β1 integrins, the α3β1 heterodimer
specifically mediates intercellular adhesion during the transition from
migratory to stationary phenotype in cultured keratinocytes, which is
associated with unique signaling events and growth inhibition
(Symington et al, 1993). Moreover, HB-EGF, CD9 (the diphtheria
toxin receptor-associated protein, DRAP27), and α3β1 integrin
coimmunoprecipitate and cross-link in situ and colocalize by immuno-
labeling at cell contact sites, coordinately with α-catenin, vinculin, and
other cytoskeletal components (Nakamura et al, 1995). Thus, the
evidence now establishes a direct link between HB-EGF and cell
adhesion molecules. This link provides a potential means to coordinately
regulate autocrine signaling by AR and HB-EGF through the EGFR
during matrix and intercellular reorganization.
AUTOCRINE NETWORKS IN SKIN DISORDERS
Preliminary characterizations have been made of AR expression at the
mRNA and protein levels in developing skin and cutaneous disorders.
The expression of AR protein is developmentally regulated in a
spatial- and time-dependent fashion during human skin morphogenesis
(Piepkorn et al, 1995). Immunolabeling and northern analyses have
indicated that AR is low to undetectable in normal adult epidermis
and markedly over-expressed in some neoplastic and non-neoplastic
hyperproliferative disorders of the epidermis (Cook et al, 1992a; Hardas
et al, 1992; Elder et al, 1993; Piepkorn, 1996). These include appendageal
tumors, actinic keratoses, verrucae, and squamous cell carcinomas
(Piepkorn, 1996). There is especially strong immunostaining in the
cytoplasm of keratinocytes within psoriatic epidermis, in contrast to
the sparse, focal labeling restricted to keratinocyte nuclei in normal
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Figure 4. Induction of keratinocyte auto-
crine growth factors under pathologic
stimuli mediates the hyperproliferative
phenotype. AR, HB-EGF, and TGF-α are
upregulated by uncharacterized mechanisms
during epidermal wounding, with neoplastic
development, and during ex vivo culturing,
resulting in pathologic hyperproliferation of
epidermal keratinocytes (A). In the case of
psoriasis, there is evidence that autocrine induc-
tion by wounding (the Koebner reaction) is
associated with the parallel recruitment of an
inflammatory response (B). T cell derived factors
may then further activate autocrine signaling in
a positive feedback loop.
skin, which correlates well with the dramatically elevated mRNA
expression of AR in involved psoriatic skin (Cook et al, 1992a;
Piepkorn, 1996). This observation raises the possibility that upregulation
of the AR signaling axis contributes to the phenotypic expression
of psoriasis.
A mediating function for aberrant expression of AR in the psoriatic
phenotype has been further tested by the recent construction and
expression of a transgene encoding a keratin 14 promoter-driven
human AR gene in the basal epidermis of mice (Cook et al, 1997).
Affected mice demonstrated limited life-spans, prominent scaling and
erythematous skin with alopecia, and occasional papillomaltous epi-
dermal growths. Histologic examination revealed extensive areas of
marked hyperkeratosis with focal parakeratosis, acanthosis, dermal and
epidermal lymphocytic and neutrophilic infiltration, and dilated blood
vessels within the papillary dermis. Our recent results have revealed
that AR may exert activities in the skin that are distinct from that of
transgenic TGF-α or other cytokines (IL-1α, TNF-α, IFN-χ, IL-6),
and induces a cutaneous pathologic state with many similarities to
psoriasis. Our observations also establish a link between the keratinocyte
EGF receptor-ligand axis and psoriatic inflammation. Collectively,
these results suggest that aberrant expression of AR in the epidermis
could represent a critical step in the development of psoriatic lesions.
Thus, the K14-AR transgenic mouse emerges as a potential model
system for study of the psoriatic phenotype.
AR and HB-EGF may also mediate critical events in the cutaneous
wounding response, including re-epithelialization and epidermal barrier
function (Liou et al, 1997; Stoll et al, 1997). AR and HB-EGF
transcripts are rapidly and strongly induced in skin organ culture, and
these effects were markedly inhibited by the addition of neutralizing
antibody to the EGFR or a potent EGFR-specific tyrosine kinase
inhibitor (PD 153035) (Stoll et al, 1997). In vivo studies involving the
disruption of the epidermal barrier by tape-stripping or acetone
treatment showed a marked (12–30-fold) increase of AR, but not
TGF-α, mRNA in murine epidermis (Liou et al, 1997). Collectively,
these findings may provide an explanation for the role of autocrine
growth factors in epidermal repair as well as the dysregulated expression
and activity that contribute to the exaggerated isomorphic (Koebner)
response in psoriasis (Cook et al, 1997) (Fig 4).
CONCLUSIONS
The signaling axis of the EGFR and its specific ligands plays a pivotal
role in the autonomous proliferative capacity of cultured keratinocytes.
Alternatively spliced CD44 proteoglycans as well as other membrane-
associated proteins (CD9) and proteoglycans are candidate cofactors in
this signaling pathway. Whereas AR and HB-EGF are principal ligands
mediating autocrine growth, distinct functions for AR are suggested
by its alternate sites of segregation to keratinocyte nuclei and to
filopodia. The nuclear distribution implies transcriptional effects, which
could correlate with both growth inhibition in human keratinocytes
and mitogenic stimulation in other cell types. These speculative
mechanisms may correspond to the original prediction from growth
assays with transformed cells that AR mediates bifunctional effects
(Shoyab et al, 1988) or other biologic properties distinct from that of
either TGF-α or EGF, such as cell density-dependent mitogenic
responsiveness and regulation by heparin or heparin-like factors (Cook
et al, 1991a, b). Additional functions for the growth factor, probably
in the form of membrane-anchored pro-AR, as a transducer of matrix
interactions are suggested by the immunolabeling of filopodia at the
outer leading edge of keratinocyte colonies (Piepkorn et al, 1995;
Nylander et al, 1998). The validity of this suggestion is supported by
the observation that HB-EGF coimmunoprecipitates and cross-links
with α3β1 integrin (Nakamura et al, 1995). What the actual growth
regulatory consequences might be of this physical interaction of an
autocrine growth factor with an integrin-class matrix receptor remain
to be elucidated. Moreover, we have recently reported that most of
the clinical and histologic features of psoriasis can be produced by
transgenically expressing AR in the basal epidermis of mice. These
results link the aberrant activity of the epidermal keratinocyte EGF
receptor-ligand system to the cutaneous inflammatory component of
psoriasis. Other investigations have established that AR, HB-EGF, and
TGF-α activity may play important roles in cutaneous wound healing,
epidermal development, and epidermal tumor development. Thus,
further investigations are warranted to determine the significance of
these growth factors in both normal and abnormal skin physiology.
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